TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8065835
Drug: Low-dose surfactant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose surfactant (100 mg/kg, max 300 mg/kg)
Study: 8065835
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment schedules (high-dose and low-dose)
Study: 28049190
Drug: <sup>131</sup>I treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: <sup>131</sup>I treatment
Study: 28049190
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment in combination with <sup>131</sup>I treatment
Study: 28049190
Drug: RTX in
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX in combination with <sup>131</sup>I treatment
Study: 12777589
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 micro g/d (max 400 micro g/d if uncontrolled)
Study: 12777589
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS) 8 mg/d (max 16 mg/d if uncontrolled)
Study: 11127339
Drug: Rice powder
Normalized name: White rice powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice powder salt solution and milk-rice mixture (RPSS-MR group, n = 17)
Study: 11127339
Drug: Glucose-based oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based oral rehydration solution combined with milk-rice mixture (ORS-MR group, n = 17)
Study: 11127339
Drug: Glucose-based oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based oral rehydration solution combined with formula milk (ORS-milk group, n = 14)
Study: 16709595
Drug: Diuretic use
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic use
Study: 29462033
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose epinephrine plus tranexamic acid
Study: 29462033
Drug: Topical diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diluted epinephrine plus tranexamic acid
Study: 24343823
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (TH) for 72 hours, maintaining rectal temperature at 33-34°C
Study: 19627552
Drug: Single-dose breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose breast milk
Study: 19627552
Drug: Single-dose sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sterile water
Study: 19627552
Drug: Single-dose 12.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 12.5% sucrose
Study: 19627552
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses breast milk
Study: 19627552
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses sterile water
Study: 19627552
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses 12.5% sucrose
Study: 11929799
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir (2 g) 4 times daily until week 18 after transplantation
Study: 11929799
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg) 4 times daily until week 18 after transplantation
Study: 8546282
Drug: Intrathecal pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal pethidine hydrochloride 0.50 mg.kg‐1
Study: 8546282
Drug: Intrathecal pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal pethidine hydrochloride 0.75 mg.kg‐1
Study: 8546282
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 13.75 mg
Study: 2468931
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of synthetic human natriuretic peptide (4‐28 hANP) at doses of 50, 100, 200, and 500 micrograms.
Study: 2468931
Drug: Vehicle administered
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle administered randomly between doses of hANP.
Study: 29343088
Drug: Promotion messages
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promotion messages (e.g., 'Live your best life - Take your medications')
Study: 29343088
Drug: Prevention messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention messages (e.g., 'team up with your provider to create a combination of medications to prevent illness')
Study: 27397061
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fenofibrate (200 mg/day or 160 mg/day) and ezetimibe (10 mg/day)
Study: 17076980
Drug: Ezetimibe monotherapy
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe monotherapy
Study: 27397061
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fenofibrate and ezetimibe
Study: 22395779
Drug: Aminophylline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (75 mg intravenous)
Study: 20880999
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² plus gemcitabine 1 gm/m² (group A) on days 1 and 8 every 3 weeks
Study: 20880999
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m² plus vinorelbine 22.5 mg/m² (group B) on days 1, 8 and 15 every 4 weeks
Study: 26179754
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once-daily
Study: 19905891
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir twice-daily
Study: 19905891
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once-daily and Insulin detemir twice-daily
Study: 16846400
Drug: Tadalafil 20-mg
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20-mg taken 'as needed'
Study: 6347118
Drug: Disulfiram (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (125 mg/day for 7 days, then 250 mg/day for 36 weeks)
Study: 25545549
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate lotion (reference)
Study: 10443240
Drug: Tularemia live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tularemia live vaccine (TLV) immunization given 15-20 days before surgery
Study: 7756706
Drug: Gentamicin 6
Normalized name: gentamicin 60 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 6 mg/kg
Study: 26822630
Drug: Pioglitazone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 7.5 mg daily for 8 weeks
Study: 22232462
Drug: High-fat breakfast
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat breakfast with moxidectin (8 mg)
Study: 22232462
Drug: Fasted subjects
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted subjects with moxidectin (8 mg)
Study: 20951424
Drug: RG7128 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7128 (1000 mg twice daily) and danoprevir (900 mg twice daily)
Study: 17949396
Drug: Murex HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murex HIV antigen/antibody combination enzyme immunoassay
Study: 16117821
Drug: Methylprednisolone i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone i.v. pulses for 2 weeks followed by oral prednisone for 4 months
Study: 10425981
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution iontophoresis (Control)
Study: 2339974
Drug: Hyoscine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (0.6 mg)
Study: 441422
Drug: Intracervical application
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical application of 0.1, 0.2 or 0.3 mg PG‐E2 in 1 ml viscous gel
Study: 21272047
Drug: Rabeprazole-DR 20
Normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole-DR 20 mg
Study: 15134239
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (e.g., warfarin)
Study: 15134239
Drug: Anti-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vitamin K drugs (warfarin)
Study: 15134239
Drug: Prior anticoagulant
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior anticoagulant treatment before cardioversion
Study: 2962712
Drug: 3% foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% foscarnet cream
Study: 2962712
Drug: Placebo (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cream vehicle)
Study: 29943624
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment in SHARP eligible patients
Study: 29943624
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment in SHARP non-eligible patients
Study: 26480664
Drug: GLP-1 analogue
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 analogue and metformin hydrochloride
Study: 26480664
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and metformin hydrochloride
Study: 21682834
Drug: Avandamet (rosiglitazone/metformin)
Normalized name: metformin hydrochloride / rosiglitazone Oral Tablet [Avandamet]
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avandamet (rosiglitazone/metformin)
Study: 11333290
Drug: Tamoxifen (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (continued therapy)
Study: 7704288
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg b.i.d for 6 weeks)
Study: 24115478
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) administered chairside during dialysis for 3 months
Study: 23878604
Drug: Once-weekly yoga
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly yoga classes (n = 49)
Study: 23878604
Drug: Twice-weekly yoga
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly yoga classes (n = 46)
Study: 21159050
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) combined with donepezil, 30-minute sessions weekly for 7 weeks.
Study: 7727669
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and injectable meglumine antimonate (20 mg of antimony [Sb]/kg.d) for 10 days and 7 days respectively
Study: 7727669
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and injectable meglumine antimonate (20 mg of antimony [Sb]/kg.d) for 10 days and 3 days respectively
Study: 2523657
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 to 7.5 mg twice daily)
Study: 127945
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G, 4.8 million units intramuscularly plus 1 g of oral probenecid
Study: 30858230
Drug: Low-trigger group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-trigger group (hemoglobin < 8.0 g/dL)
Study: 30858230
Drug: High-trigger group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-trigger group (hemoglobin < 9.7 g/dL)
Study: 25867874
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion 0.02 mg/kg/h after 0.1 mg/kg iv bolus
Study: 25867874
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 0.25 µg/kg/min following 1 µg/kg iv bolus
Study: 25867874
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion 0.50 µg/kg/min following 10 µg/kg iv bolus
Study: 25867874
Drug: Saline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 5 cc iv bolus and 10 cc/h infusion for induction and maintenance
Study: 17485570
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/metformin 2,000 mg (S100/M2000)
Study: 17485570
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/metformin 1,000 mg (S100/M1000)
Study: 17485570
Drug: Metformin 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2,000 mg (M2000)
Study: 17485570
Drug: Metformin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,000 mg (M1000)
Study: 17485570
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg (S100)
Study: 17485570
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/metformin 2,000 mg (S100/M2000) in open-label cohort
Study: 17485570
Drug: Co-administration therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration therapies vs respective metformin monotherapy
Study: 10102256
Drug: Sibutramine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 30 mg/day
Study: 7993330
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (stimulus control, urge control, contracting/family support, competing response procedures) for an average of 19 sessions
Study: 7993330
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment (alternative treatment)
Study: 2951426
Drug: Ordinary dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary dosage of ipratropium (80 micrograms four times a day)
Study: 2951426
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy of ipratropium (400 micrograms four times a day)
Study: 25355680
Drug: Adjuvant procarbazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy after 54 Gy of radiotherapy (RT)
Study: 23193678
Drug: Qianlieping Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlieping Capsule plus tamsulosin
Study: 23193678
Drug: Qianlieping Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlieping Capsule alone
Study: 15223898
Drug: Two-dose basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two-dose basiliximab with low initial CsA triple therapy (group B)
Study: 15223898
Drug: Conventional triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional triple therapy (group C)
Study: 11725330
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/d for 6 days, then 6 g/d for 4 weeks)
Study: 8215564
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage surfactant regimen (100 mg/kg initially, with two further doses at 12 and 24 hours to a maximum cumulative total of 300 mg/kg; n = 1069)
Study: 8215564
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage surfactant regimen (200 mg/kg initially with up to four further doses of 100 mg/kg to a maximum cumulative total of 600 mg/kg; n = 1099)
Study: 8215564
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage surfactant regimen
Study: 8215564
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage surfactant regimen
Study: 31515428
Drug: Methotrimeprazine 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrimeprazine 6.25 mg
Study: 31515428
Drug: Haloperidol 1.5
Normalized name: haloperidol 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1.5 mg
Study: 26975312
Drug: Transregional interferential
Normalized name: thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transregional interferential current therapy (10 sessions of 25 minutes over two weeks)
Study: 24273182
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA vaccine in H. pylori infected subjects
Study: 24273182
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA vaccine in subjects with low PG I:PG II ratio (<5)
Study: 24273182
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA vaccine in H. pylori uninfected subjects
Study: 24273182
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA vaccine with Hepatitis A infection
Study: 22938439
Drug: Continuous transarterial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transarterial infusion chemotherapy with gemcitabine (1000 mg/m2) and 5-Fluorouracil (600 mg/m2)
Study: 22938439
Drug: Systemic venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic venous chemotherapy with gemcitabine (1000 mg/m2) and 5-Fluorouracil (600 mg/m2)
Study: 15205720
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ALN
Study: 15205720
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ALN
Study: 15205720
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ALN
Study: 3305850
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and diuretics
Study: 3305850
Drug: Theophylline and
Normalized name: theophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline and diuretics
Study: 18270772
Drug: Conventional laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laparoscopic tumor-specific mesorectal excision (L-TSME)
Study: 15745109
Drug: Beta-blockers (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (group B; n = 15)
Study: 7750282
Drug: Nestorone subdermal
Normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone subdermal implant (Implant A)
Study: 7750282
Drug: Nestorone subdermal
Normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone subdermal implant (Implant B)
Study: 7750282
Drug: Nestorone subdermal
Normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone subdermal implant
Study: 7350294
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (hGH)
Study: 7350294
Drug: Oxandrolone +
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone + Human growth hormone (Ox + hGH)
Study: 28638060
Drug: Epidural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural group (Group E): TEA with levobupivacaine and dexmedetomidine, intravenous saline infusion
Study: 28638060
Drug: Intravenous group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous group (Group V): TEA with levobupivacaine, intravenous dexmedetomidine infusion
Study: 28638060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C): TEA with levobupivacaine alone, intravenous saline infusion
Study: 25854859
Drug: Pradigastat (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat (1, 3, 10, 30, 100, or 300 mg)
Study: 25854859
Drug: Pradigastat (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat (1, 5, 10, or 25 mg)
Study: 25854859
Drug: Pradigastat (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat (single and multiple doses)
Study: 24088535
Drug: Mindfulness Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Based Stress Reduction (MBSR) Intervention I (weekly group sessions + self‐instructing program)
Study: 21843685
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally
Study: 17920976
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (INF) 180 mug +/‐ 2 doses of 60 mug at > or =5‐minute intervals
Study: 17920976
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IVM) 2.5 to 5 mg +/‐ 2 doses of 2.5 to 5 mg at > or =5‐minute intervals